Prognostic Value of Interim SPECT/CT in Prostate Cancer Therapy: Meta-Analysis Results

A systematic review and meta-analysis of seven studies involving 648 patients evaluates the prognostic value of interim post-treatment SPECT/CT imaging following lutetium-177-PSMA therapy for metastatic castration-resistant prostate cancer. The analysis, conducted by Amirreza Shamshirgaran and published on figshare in April 2026, pooled hazard ratios for survival outcomes based on imaging parameters. It found that the emergence of new lesions and increases in total tumor volume were associated with worse overall and PSA-progression-free survival.

Use Cases

• Evaluating the prognostic significance of new lesion detection on SPECT/CT scans for survival modeling.
• Assessing the relationship between changes in total tumor volume (TTV) and patient outcomes.
• Comparing the predictive value of different SPECT/CT parameters (e.g., SUVmean, SUVmax) for clinical response.
• Supporting the standardization of imaging protocols for early response assessment in radioligand therapy.

Strengths

• Analysis follows PRISMA guidelines and PICO framework, indicating a structured methodological approach.
• Includes data from seven studies totaling 648 patients, providing a pooled evidence base.
• Results include specific pooled hazard ratios with confidence intervals and p-values for key parameters like new lesions and TTV.

Limitations

• The dataset is a 13.9 KB document (DOCX), suggesting it contains summary results rather than raw patient-level data.
• Column-level documentation is absent; field semantics must be inferred from the manuscript.
• Row count is unknown, which may limit suitability assessment for direct computational analysis.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of studies from PubMed/MEDLINE, Scopus, and Google Scholar.

Time Range

Studies searched up to December 2025.

Freshness

Last updated 2026-04-24 04:21:32